Momelotinib Bests Danazol in Symptomatic, Anemic Myelofibrosis
Momelotinib proved superior to danazol in patients with symptomatic, anemic myelofibrosis in a phase 3 study.
Momelotinib proved superior to danazol in patients with symptomatic, anemic myelofibrosis in a phase 3 study.
Gender balance in cancer surveys of patients with myeloproliferative neoplasms was found to have relatively little effect on survey outcomes.
Researchers sought to determine whether inhibiting ROCK1/2 when using interferon therapy would be effective in patients with MPNs.
Researchers sought to determine whether there is a link in loss of LMNB1 expression with changes in myeloid neoplasms.
A retrospective study sought to determine the response to azacitidine in patients with CMML applying the overlap MDS/MPN response criteria.
Researchers sought to determine the prevalence of frailty among patients with myeloproliferative neoplasms.
A team of researchers presented their strategies for choosing patients with myelofibrosis who may be candidates for allogeneic stem cell transplantation and guiding their treatment.
Researchers sought to characterize features and outcomes specific to patients with MDS and MPNs with ring sideroblasts and thrombocytosis.
Analysis of data from 2 clinical trials sought to determine the effect on symptom burden of 2 common therapies for myeloproliferative neoplasms.
Researchers sought to determine whether the tumor suppressor gene CADM1 would be a factor influencing MDS with del(11q).